Φορτώνει......
Bifeprunox versus placebo for schizophrenia
BACKGROUND: Bifeprunox is a novel antipsychotic drug designed to treat schizophrenia. However, research into the drug was ceased in 2009 due to rejection of licence to go to market by the US Food and Drug Administration (FDA), who could not approve the drug for acute or long‐term symptoms of schizop...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Cochrane Database Syst Rev |
|---|---|
| Κύριοι συγγραφείς: | , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
John Wiley & Sons, Ltd
2016
|
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6457956/ https://ncbi.nlm.nih.gov/pubmed/27732740 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD012029.pub2 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|